Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis

Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL · Feb 6, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) and Progressive Fibrotic Interstitial Lung Disease, conditions that cause serious lung scarring and difficulty breathing. The researchers want to see if using a patient’s own lung stem cells, called Lung Spheroid Stem Cells (LSCs), is safe and effective when given through an intravenous (IV) infusion. A total of 24 participants will be involved, some receiving the LSC treatment and others receiving standard care for their condition.

To be eligible for the trial, participants must be between 40 and 80 years old and have a confirmed diagnosis of IPF or Progressive Fibrotic Interstitial Lung Disease. They also need to have certain lung function measurements that show they can participate safely. If someone joins the trial, they can expect to receive either the new treatment or standard care and will be monitored closely for up to two years after receiving the infusion. This study is currently recruiting participants, and all patients will continue to receive their routine care for their lung condition throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female between the ages of 40 to 80.
• • Diagnosis of a Progressive Fibrotic Interstitial Lung Disease
• * Diagnosis of IPF based on the following criteria in accordance with American Thoracic Society (ATS) guidelines for diagnosing IPF:
• • 1. Definite usual interstitial pneumonia (UIP) confirmed on surgical lung biopsy (SLB) with all other etiologies for UIP excluded OR High resolution CT scan (HRCT) showing definite UIP with all other etiologies for UIP excluded.
• • 2. Probable UIP on both imaging and surgical lung biopsy with all other etiologies for UIP excluded.
• • Forced vital capacity (FVC) greater than 50% of predicted with a ratio of forced expiratory volume in 1 second to FVC (FEV1/FVC) greater than 0.75 (Pulmonary function tests must be completed no more than 90 days before screening).
• • Diffusing capacity for carbon monoxide (DLCO) greater than 25% of predicted capacity.
• • Ability to perform a 6-Minute Walk Test (6MWT) at screening.
• • Competency to understand the information given in the Human Research and Ethics Committee (HREC) approved Informed Consent Form and must sign the form prior to the initiation of any study procedures
• Exclusion Criteria:
• • Diagnosis of an interstitial lung disease (ILD) or restrictive lung disease other than IPF or Progressive Fibrotic Interstitial Lung Disease.
• • Obstructive lung disease as determined by evidence of airflow obstruction on HRCT or physiologic criteria including: FEV1/FVC ratio less than 0.75, Residual volume (RV) greater than 120% by plethysmography or significant (verified by radiologist) emphysema on HRCT or evidence of reactive airway disease by change in FEV1 of greater than 12% following bronchodilator challenge.
• • Evidence of sustained improvement lung function defined as improvement from pre-therapy pulmonary function tests (PFTs) observed with two or more successive post-therapy PFTs over the year prior to randomization.
• • Active or recent (less than 60 days prior to enrollment) significant respiratory tract infections, or a history of frequent (greater than 2 per year for the last 2 years) infective exacerbations of IPF.
• • Hospitalization within 60 days of screening for an acute exacerbation of IPF (AE-IPF).
• • Chronic heart failure (NYHA class III/IV) or known left ventricular ejection fraction less than 45%.
• • Acute or chronic impairment (other than dyspnea) which limits the ability to comply with study requirements and procedures including the 6MWT.
• • Subject requires hemodialysis, peritoneal dialysis or hemofiltration.
• • Infection with HIV
• • Viral Hepatitis
• • Resting oxygen requirements or \>4 L of nasal canula oxygen needed with exertion